This activity is expired and is no longer available for CME credit.


Revolutionizing the Treatment of Neovascular Retinal Disease by Targeting the Angiopoietin-Tie Pathway

Author(s)/Faculty: Rishi P. Singh, MD; Dilsher S. Dhoot, MD; Arshad M. Khanani, MD, MA
Release Date: 8/22/2018Expiration Date: 8/21/2019
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
The treatment of neovascular retinal disease has been revolutionized by the utilization of intravitreal anti-vascular endothelial growth factor (VEGF) therapy. However, optimal benefit is not always received by patients receiving anti-VEGF therapy, demonstrating a need for the identification of other molecular pathways that can be targeted by novel therapies. Molecular pathways involved in abnormal angiogenesis and increased vascular permeability are attractive targets for therapy and are currently being assessed in clinical studies. One such promising pathway is the Tie2 angiogenic pathway, and novel agents targeting this pathway are currently being assessed for the treatment of neovascular retinal disease. In this live educational activity, experts in the field will review the need for alternatives to anti-VEGF monotherapy, discuss pathophysiologic mechanisms behind the Tie2 signaling pathway, evaluate the most recent efficacy and safety data for investigational agents that target the Tie2 angiogenic pathway in neovascular disease, as well as provide insight as to how these agents may modify the paradigm of current treatment algorithms.